✦ LIBER ✦

ADJUVANT INTERFERON TREATMENT FOR MELANOMA

✍ Scribed by Agarwala, Sanjiv S.; Kirkwood, John M.

Book ID: 121771332
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 683 KB
Volume: 12
Category: Article
ISSN: 0889-8588
DOI: 10.1016/S0889-8588(05)70025-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon as adjuvant treatment for mel

Interferon as adjuvant treatment for melanoma

✍ Keith Wheatley; Natalie Ives; Barry Hancock; Martin Gore 📂 Article 📅 2002 🏛 The Lancet 🌐 English ⚖ 51 KB

Intermediate dose interferon alpha in ad

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma

✍ Faruk Tas; Sidika Kurul; Hakan Camlica; Erkan Topuz 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 65 KB

Combined interferon-α and interleukin-2

Combined interferon-α and interleukin-2 as adjuvant treatment for melanoma

✍ Reinhard Dummer; Axel Hauschild; Tilo Henseler; Günter Burg 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 55 KB

Severe loss of vision during adjuvant in

Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma

✍ Chris P Lohmann; Gisela Kroher; Thomas Bogenrieder; Detlev Spiegel; Jürgen Preun 📂 Article 📅 1999 🏛 The Lancet 🌐 English ⚖ 61 KB

Cochrane Database of Systematic Reviews

Cochrane Database of Systematic Reviews (Reviews) || Interferon alpha for the adjuvant treatment of cutaneous melanoma

✍ Mocellin, Simone 📂 Article 📅 2013 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 845 KB

Practical guidelines for the management

Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion

✍ Axel Hauschild; Helen Gogas; Ahmad Tarhini; Mark R. Middleton; Alessandro Testor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract Interferon‐α‐2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from t